FONAR Corporation

NASDAQ:FONR

Medical - Devices

Healthcare
$19.09 +0.00%

+$0.00 today

Market cap
$117.76M
Beta
0.95
P/E (TTM)
17.6
EPS (TTM)
$1.08
52W Low $13.62High $19.16

Volume 0.00M

Average 0.08M

FONR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

FONAR CorporationNASDAQ: FONR

Selling, General & Admin · Q3 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q3 FY2026 selling, general & admin of $8.37M rose 4.8% year over year, behind the +168.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 34.2% from the prior quarter.

Context

  • Selling, general & admin amounted to 28.5% of revenue in FY2025, up 28.5 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +4.8% toward the trailing-twelve-month pace of +168.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.37M+34.2% QoQ
Last fiscal yearJun 2025
$29.73M— YoY
LTMMar 2026
$21.42M+168.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.8%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
29.73M USD
Year-over-year change
—

Selling, General & Admin vs competitors

How FONR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +168.1% is the highest of 8, against a peer median of -4.4%.
  • Selling, general & admin amounts to 20.3% of revenue for FONR, versus a peer median of 112.1%.
FONR Competitors
Selling, General & Admin for FONR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LUNGPulmonx CorporationLTM Mar 2026$99.26M USD-4.4%+6.8%112.1%
RCELAVITA Medical, Inc.LTM Mar 2026$78.19M USD-14.1%+20.9%108.1%
APYXApyx Medical CorporationLTM Mar 2026$31.78M USD-9.7%-9.1%56.8%
HYPRHyperfine, Inc.LTM Mar 2026$26.33M USD-2.2%-17.3%171.8%
FONRFONAR CorporationLTM Mar 2026$21.42M USD+168.1%—20.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$20.27M USD+8.2%-0.8%—
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
VANIVivani Medical, Inc.LTM Mar 2026$9.52M USD+9.5%+20.6%—
Peer median (excluding FONR) —-4.4%+6.8%112.1%

Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue89.93M97.59M98.65M102.88M104.35M
Cost of Revenue46.46M50.58M52.9M57.74M61.44M
Gross Profit43.47M47.01M45.75M45.14M42.91M
Gross Margin48.3%48.2%46.4%43.9%41.1%
Research & Development1.64M1.49M1.57M1.74M1.58M
Selling, General & Admin0029.39M029.73M
Operating Expenses26.38M25.01M30.96M28.6M31.31M
Depreciation & Amortization4.08M4.54M8.8M4.6M4.7M
EBITDA22M27.65M24.61M23.94M18.5M
EBITDA Margin24.5%28.3%25.0%23.3%17.7%
Operating Income17.1M22.01M14.79M16.54M11.6M
Operating Margin19.0%22.6%15.0%16.1%11.1%
Interest Income00002.17M
Interest Expense248.67K346.55K50.13K77K25.61K
Other Income / Expenses567.72K761.69K969.33K2.73M2.18M
Income Before Tax17.67M22.77M15.76M19.27M13.78M
Pre-Tax Margin19.6%23.3%16.0%18.7%13.2%
Income Tax Expense3.99M5.53M3.63M5.17M3.11M
Net Income10.21M12.44M9.38M10.57M8.33M
Net Margin11.4%12.7%9.5%10.3%8.0%
EPS (Basic)1.471.781.351.561.26
EPS (Diluted)1.451.751.321.531.23
Weighted Avg Shares6.61M6.55M6.65M6.35M6.32M
Weighted Avg Shares (Diluted)6.74M6.68M6.77M6.48M6.55M

FONAR Corporation

NASDAQ:FONR

Intrinsic Alpha fair value

Locked

Current Price

$19.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.